Contributions to drug resistance in glioblastoma derived from malignant cells in the sub-ependymal zone. by Piccirillo, SG et al.
Contributions to drug resistance in glioblastoma derived from 
malignant cells in the sub-ependymal zone
Sara GM Piccirillo1,†, Inmaculada Spiteri#2, Andrea Sottoriva#2,3, Anestis Touloumis2,4, 
Suzan Ber1, Stephen J Price5, Richard Heywood1, Nicola-Jane Francis6, Karen D Howarth7, 
Vincent P Collins8, Ashok R Venkitaraman6, Christina Curtis3, John C Marioni4, Simon 
Tavaré2, and Colin Watts1,5,†
1John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of 
Cambridge, Cambridge, UK
2Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Cambridge, UK
3Department of Preventive Medicine, Keck School of Medicine, University of Southern California, 
Los Angeles, California, USA
4European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Hinxton, 
Cambridge, UK
5Division of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, 
Addenbrooke’s Hospital, Cambridge, UK
6Department of Oncology and the Medical Research Council Cancer Cell Unit, Hutchison/MRC 
Research Centre, Cambridge, UK
7Hutchison/MRC Research Centre and Department of Pathology, University of Cambridge, 
Cambridge, UK
8Division of Molecular Histopathology, Department of Pathology, University of Cambridge, 
Addenbrooke’s Hospital, Cambridge, UK
#
 These authors contributed equally to this work.
Abstract
†To whom correspondence should be addressed. sp577@cam.ac.uk (S.G.M.P.); cw209@cam.ac.uk (C.W.).
Author Contributions
S.G.M.P. designed and performed the experiments, collected, analyzed and interpreted the data and wrote the manuscript. I.S. 
performed experiments, collected, analyzed and interpreted the data and contributed to manuscript preparation. A.S. contributed to the 
design of the tissue multi-sampling scheme for phylogeny, analyzed and interpreted the data and contributed to manuscript 
preparation. A.T. contributed to data analysis. S.B. performed experiments. S.J.P. provided tissue samples. R.H. collected tissue 
samples. N.F. reviewed and edited the manuscript. K.D.H. performed experiments. V.P.C. performed histopathological analysis, 
reviewed and edited the manuscript. A.R.V. reviewed and edited the manuscript. C.C. generated and interpreted the data, reviewed 
and edited the manuscript. J.C.M. reviewed and edited the manuscript. S.T. designed the overall study, supervised the project, 
interpreted the data and edited the manuscript. C.W. designed the overall study, supervised the project, provided tissue samples, 
contributed to the design of the tissue multi-sampling scheme for phylogeny, interpreted the data and edited the manuscript. All 
authors discussed the results and commented on the manuscript.
Disclosure of conflicts of interest
The authors disclose no potential conflicts of interest.
Author Information
The data reported in this paper are deposited in ArrayExpress (accession codes E-MTAB-1129 and E-MTAB-1215).
Europe PMC Funders Group
Author Manuscript
Cancer Res. Author manuscript; available in PMC 2015 July 01.
Published in final edited form as:
Cancer Res. 2015 January 1; 75(1): 194–202. doi:10.1158/0008-5472.CAN-13-3131.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Glioblastoma (GB), the most common and aggressive adult brain tumor, is characterized by 
extreme phenotypic diversity and treatment failure. Through fluorescence-guided resection, we 
identified fluorescent tissue in the sub-ependymal zone (SEZ) of GB patients. Histological 
analysis and genomic characterization revealed that the SEZ harbors malignant cells with tumor-
initiating capacity, analogous to cells isolated from the fluorescent tumor mass (T). We observed 
resistance to supra-maximal chemotherapy doses along with differential patterns of drug response 
between T and SEZ in the same tumor. Our results reveal novel insights into GB growth 
dynamics, with implications for understanding and limiting treatment resistance.
Introduction
The basis of phenotypic diversity and treatment failure in human GB is poorly understood. 
Murine models of gliomagenesis point to sub-ependymal neural stem cells (NSCs) as a 
putative cell of origin for astrocytic tumors. The stepwise pre-malignant loss of tumor 
suppressors p53, NF1 & PTEN (1, 2) has been shown to lead to the development of an 
aggressive disease characterized by resistance to genotoxic injury (3).
Additionally, stratifying patients using transcriptional profiles derived from a large cohort of 
GB single tumor samples (4) has identified multiple disease subtypes, which may have 
prognostic significance (5, 6). However, emerging data on genomic intra-tumor 
heterogeneity in GB indicate spatial segregation of genetically distinct clones in the same 
tumor (7), making the interpretation of single-sample tumor data challenging. Importantly, 
this may contribute to the pervasive failure of treatment in GB patients.
Clinical trials have established that use of a fluorescence biomarker, 5-aminolevulinic acid 
(5-ALA), can enhance the surgical resection of GB (8). We have demonstrated the use of 5-
ALA in a Fluorescence-Guided Multiple Sampling (FGMS) strategy that permits real-time 
spatially segregated tumor sampling during surgery (7, 9). Combining visible fluorescence 
with neuroanatomy allows for the objective distinction of the tumor mass T (visible 
fluorescent). Importantly, a spatially distinct and visibly fluorescent sub-ependymal zone 
(SEZ) can also be identified in a subset of GB patients.
Here we report an integrated genomic analysis of SEZ and T samples, obtained by FGMS, 
which reveals that malignant cells in the SEZ contribute to tumor growth. Functional 
characterization confirms that the SEZ contains tumor-initiating cells (TICs) that can 
recapitulate the disease in orthotopic patient-derived xenogeneic models in a manner similar 
to TICs isolated from the corresponding T. TICs in the SEZ contribute to resistance to 
chemotherapy and show differential patterns of response when compared to T of the same 
patients.
Materials and Methods
GB sample collection
Patient informed consent was obtained through our research clinic (10). Tissue collection 
protocols were compliant with the UK Human Tissue Act 2004 (HTA Licence ref 12315) 
and approved by the Local Regional Ethics Committee (LREC ref 04/Q0108/60). No 
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difference in 5-ALA labeling capacity was observed among patients. See Supplementary 
Experimental Procedure for details on 5-ALA administration and sample collection.
Quantitative Real-time PCR analysis
Total RNA was extracted from T and SEZ tissues using TRIzol (Invitrogen) according to the 
manufacturer’s instructions. RNA was treated with DNase (Qiagen) and cDNA was 
synthesized from 5μg of total RNA using Random Primers (Invitrogen) and a Superscript III 
First-Strand Synthesis System for real-time PCR (RT–PCR) (Invitrogen). The RT–PCR for 
Nestin, Gfap, Sox2 and MIB1 transcripts was performed using CFX96 RT–PCR (Biorad), 
RT2 qPCR Primer Assay and SYBR Green Master Mix (Qiagen) according to the 
manufacturer’s instructions. 18S was used as the housekeeping reference. Relative 
expression quantification was performed by the ΔΔCT method. Experiments were performed 
in triplicate and each experiment was repeated 3 times.
Cell line derivation and implantation
Cell cultures from T and SEZ of 42 patients were established from GB patients undergoing 
surgery at Addenbrooke’s Hospital, Cambridge, in 2010-2012. The cells were isolated as 
described (9, 11, 12) and used either uncultured (primary) or propagated in vitro for 2 
passages (briefly cultured) in serum-free medium. The U87 cell line was obtained from the 
American Type Culture Collection, cultured according to the supplier’s recommendations 
and used just after resuscitation. Tissue collection to establish HFNSCs was approved by the 
Local Regional Ethics Committee. Cells were established in 2011 and grown in serum-free 
medium in order to form neurospheres and used at early passage. All the cell cultures have 
been tested for mycoplasma contamination by PCR before use. See Supplementary 
Experimental Procedure for details on cell propagation, immunofluorescence and in vivo 
experiments.
DNA and RNA extraction
DNA from T and SEZ tissues of 14 GB patients was extracted for copy number analysis 
using DNeasy Blood & Tissue Kit (Qiagen). RNA from T and SEZ tissues of 15 GB patients 
was extracted for gene expression analysis using Trizol (Invitrogen) and cleaned up using 
MiniElute columns (Qiagen). See Supplementary Experimental Procedure for details on 
copy number and gene expression analysis. Copy number results were validated by 
fluorescence in situ hybridization as described in the Supplementary Experimental 
Procedure.
Drug treatment assay
Treatment with Temozolomide, Cisplatin and Cediranib was evaluated using the in vitro 
BrdU cell proliferation assay (Millipore). 3×103 cells were plated in triplicate per treatment 
condition. Control wells for Temozolomide, Cisplatin and Cediranib are shared as these 
treatments have been applied in the same experiments. One day after plating, the treatment 
was applied for 3 days. BrdU was applied in the final 24 hours of the treatment. Each 
experiment was repeated 3 times. See Supplementary Experimental Procedure for details on 
drug concentration.
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MGMT promoter methylation
Analysis of MGMT promoter methylation was performed by PCR (13) and by 
pyrosequencing (14). In brief, DNA was bisulfite converted and subsequently subjected to 
PCRs using specific primer pairs for the methylated or the modified unmethylated DNA. 
PCR products were resolved in a 2% agarose gel stained with SybrSafe. See Supplementary 
Experimental Procedure for further details.
Phylogenetic reconstruction
Multiple spatially separated samples taken from each GB were collected in order to 
reconstruct the phylogenetic relationship between the tumor and the SEZ using copy number 
profiles and molecular clock analysis. See Supplementary Experimental Procedure for 
further details.
Statistical analysis
For in vivo experiments using Nod/Scid animals, we performed Kaplan-Meier survival 
analysis using the Logrank test for hypothesis testing.
For drug response analysis using BrdU, a one-way ANOVA was performed for each patient.
The p-values for the pairwise mean comparisons of each treatment to the corresponding 
control were calculated using Tukey’s Honestly Significant Difference test. In the related 
figures and for each patient, we plotted the normalized mean treatment response using the 
corresponding mean control as a reference, except in Supplementary Fig. 12, where we 
normalized to the mean of the 50μM TMZ treatment response. The minimum and maximum 
normalized values are provided in order to present the dispersion of the normalized data.
Results
SEZ harbors residual disease in GB patients
We screened 65 GB patients given 5-ALA and confirmed that visibly fluorescent disease 
extended to the SEZ in 65% (42/65) of the cases. Multiple samples were obtained from 14 
patients. Histological features of high-grade glioma (15) were detected in SEZ and T of the 
patients (Fig. 1A; additional two representative GBs are shown in Supplementary Fig. S1, A 
and B). SEZ tissue was also used to identify the ependymal layer and confirm correct 
sampling (Supplementary Fig. S2).
GB has been shown to heterogeneously express glial fibrillary acidic protein (Gfap) (16) and 
consistent with this we noted high expression of Gfap in SEZ samples compared to matched 
T samples (Fig. 1, B and C top panel and Supplementary Fig. S1C). Expression of the 
precursor marker Nestin was detected both in T and SEZ tissues (Fig. 1, B and C middle 
panel and Supplementary Fig. S1C). The SEZ showed increased vascularization in 
comparison to T, as determined by CD31 expression (Fig. 1, B and C bottom panel). Weak 
expression of the neuronal marker Tuj1 was observed in both areas (Supplementary Fig. 
S1C). One of the histological hallmarks of GB is high proliferative activity (17) and we 
observed similar numbers of mitotic cells in T and SEZ (MIB1 index 20.5±2.8 and 18.1±1.9 
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respectively) (Supplementary Fig. S1C). The extent of focal necrosis was similar in T and 
SEZ of the same patients (except for sp40) (Supplementary Table S1). Consistent with 
immunohistochemical analysis, T and SEZ contained similar amounts of tumor tissue 
(except for sp54) (Supplementary Table S1). Together these data suggest that regulatory 
mechanisms promoting proliferation and vascularization are common to the T and the SEZ 
tissues.
To confirm these findings we performed real-time analysis of gene expression for markers 
of glial and precursors cells (Gfap and Nestin), stem cells (Sox2), proliferation (MIB1) on T 
and SEZ tissues of 3 GBs in total (Supplementary Fig. S3). Our results show increased 
expression of Gfap in the SEZ compared with the corresponding T (Supplementary Fig. S3). 
The expression of Nestin and Sox2 is similar between T and SEZ, except in sp10 for Sox2 
(Supplementary Fig. S3).
We applied high-throughput genomic profiling techniques to the SEZ and T to characterize 
each of these regions. DNA/RNA were extracted from the tissues of the 14 patients 
(Supplementary Table S2A). After quality assessment, we analyzed copy number 
aberrations (CNAs) of 8 patients and gene expression profiles of 9 patients (6 of whom were 
common to both analyses) (Supplementary Table S2B shows the patient clinical 
information). Our data reveal multiple aberrations (e.g. EGFR amplification and CDKN2A 
deletions) common to T and the corresponding SEZ in individual patients (Fig. 2A and 
Supplementary Fig. S4). In 6/8 patients, the SEZ had an equal or smaller number of putative 
driver aberrations with respect to the corresponding T (mean difference in the number of 
aberrations is 1.27±0.38; p-value = 0.12). CNA results were validated by fluorescence in 
situ hybridization (FISH) for three GB drivers, EGFR, MET and PTEN (4), in three patients 
with available tissue (Fig. 2B and Supplementary Fig. S5, A-H). Because we observed in 
vitro aberrations in the corresponding cell cultures (Supplementary Fig. S6), we restricted 
further genomic analysis to tissue samples.
Clustering of the gene expression data (18) revealed that only 3/9 paired samples (SEZ and 
T from the same patient) clustered tightly together while 5/9 SEZ were assigned to the same 
sub-cluster, suggesting a SEZ-specific expression profile across patients (Fig. 2C).
We used a previously published classifier to assign our samples into one of 4 GB subtypes 
(6). 7/9 SEZ were classified as Mesenchymal (sp41, sp42, sp52, sp54, sp56, sp57 and r4) 
and the remaining 2 were Classical (sp49 and sp55). For 6/9 patients the SEZ was assigned 
to a different subtype than the corresponding T. T samples were distributed amongst the 4 
subtypes (Classical, Mesenchymal, Neural and Proneural) (Fig. 2D).
We next investigated whether gene expression levels differed between SEZ and T. We 
rejected the hypotheses of no significant differences in the expression levels of all genes 
between SEZ and T (p-value <0.00001), which suggests that there are differentially 
expressed genes in SEZ and T.
We next used the R package HDTD to identify gene ontology (GO) terms whose genes are 
differentially expressed (Supplementary Table S3).
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Tumor-initiating cells reside in the SEZ
We next extended the characterization of T and SEZ to TIC populations. In neuro-epithelial 
malignancies the purification of TICs remains challenging because no robust cell-surface 
marker has been identified to distinguish tumorigenic and non-tumorigenic cells (19, 20). 
Initial data identifying CD133/Prominin1 as a marker in human GB (21) were subsequently 
challenged both in primary and cultured TICs (reviewed in (19)). More recently the cell 
surface marker CD15/SSEA-1 has been identified as a possible TIC marker in GB and 
medulloblastoma (22, 23). CD15 is a carbohydrate moiety expressed by neural stem and 
progenitor cells (24) but its use as GB marker did not find additional confirmation (25).
We therefore used a marker-independent approach (9, 11, 12, 26) to isolate cells from T and 
SEZ under serum-free conditions in vitro (Fig. 3A). Growth curve analysis and limiting-
dilution assays confirmed long-term self-renewal and expansion (Fig. 3B and 
Supplementary Fig. S7), clonogenicity and multipotency similar to the corresponding T cells 
(Supplementary Fig. S8).
We evaluated the expression of the precursor marker Nestin and other putative TIC markers 
(A2B5, CD133, CD15) from T and SEZ (reviewed in (19)) and found similar expression of 
Nestin in T and SEZ cells, in agreement with the data in Fig. 1, B and C. In contrast, A2B5-, 
CD133- and CD15-positive cells were rarely found (Supplementary Fig. S9, A and B).
Despite phenotypic differences in vitro, orthotopic inoculation of T and SEZ cells in NOD-
SCID mice consistently generated tumors in all cases (Fig. 3, C and D and Supplementary 
Fig. S10). Nonetheless, a statistically significant shorter survival was observed for animals 
injected with T cells compared to those injected with SEZ cells (Fig. 3C and Supplementary 
Fig. S10; p-value <0.05).
To our knowledge, this is the first time that SEZ cells from GB patients have been tested for 
their tumorigenic potential. We analyzed the in vivo properties of enriched SEZ cells from 3 
additional GBs. In all cases SEZ cells gave rise to tumors with similar patterns of growth 
and infiltration to those generated from TICs isolated from T under the same experimental 
conditions (Supplementary Fig. S11, A-C).
TICs from the SEZ contribute to drug resistance
The SEZ and T contained self-renewing TICs suitable for chemo-response assays. These 
cells are grown in conditions that better preserve the genotype of the original disease (27) 
and have been proposed for use in high-throughput drug screening (28, 29). We tested the 
effects of the oral alkylating agent Temozolomide (TMZ), the current standard of care in GB 
patients (30). To facilitate analysis, we assayed methylation in the promoter region of 
MGMT, a methyltransferase that inhibits the cytotoxic effect of TMZ and is a predictive 
biomarker in GB (31).
We initially treated TICs isolated from T and SEZ of 7 GB patients with TMZ at maximum 
concentrations reported for the brain and plasma (50 μM) (32, 33), but no significant 
treatment response was observed relative to the corresponding controls (vehicle only). Only 
sp12 showed a significant response in both T and SEZ (Supplementary Fig. S12). We 
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therefore analyzed a set of TICs isolated from T of 20 patients using a dose escalation 
strategy ranging from 50μM to 2.5mM of TMZ, and found that only 20% of the samples 
exhibited a significant response at ≥ 500 μM (Supplementary Fig. S13, A and B).
Based on these results we performed cell proliferation assays for TMZ concentrations 
between 50 μM and 2.5mM on TICs isolated from T and SEZ of the same tumor for 8 
patients. We noted that TICs continued to proliferate in the SEZ and T at supra-maximal 
drug concentrations. We also observed that the response varied between T and SEZ of the 
same GB (Fig. 4A and Supplementary Fig. S14A). Three patterns emerged: differential 
response between T and SEZ (e.g. sp13, sp20, sp37 and sp42), both T and SEZ respond (e.g. 
sp17, sp23), neither T nor SEZ respond (e.g. sp14, except at 2.5 mM TMZ for T, and sp52).
To test whether resistance to TMZ was MGMT-dependent, we analyzed the DNA 
methylation status of the MGMT promoter by pyrosequencing (Supplementary Table S4) 
and methylation-specific PCR (13) (Supplementary Fig. S15) and we found that the results 
were in agreement except for sp42.
Our PCR analysis revealed that 4/7 paired TICs (sp14, sp23, sp37 and sp52) did not show 
methylation of the MGMT promoter in either the T or the SEZ consistent with the poor 
response to TMZ, except for sp23 (T and SEZ) and sp37T. In contrast, sp17, sp20 and sp42 
are methylated and showed a better response to TMZ among all the tested TICs with the 
exception of sp20SEZ and sp42T (Fig. 4A and Supplementary Fig. S14A). All together, our 
results suggest that MGMT methylation status is homogeneous in T and SEZ of the same 
patients and generally predicts response to TMZ (Supplementary Table S5).
We also evaluated the anti-mitotic agent Cisplatin, previously used in GB therapy, and 
Cediranib, an anti-angiogenic inhibitor of VEGFRs with additional activity against 
PDGFRs, recently used in clinical trials (34, 35) (Fig. 4B and Supplementary Fig. S14B). 
Although anti-angiogenic therapies target the endothelial compartment, it has been reported 
that VEGFRs are enriched on the surface of TICs from GB (36). VEGF signals via its 
endothelial tyrosine kinase receptor 2 (VEGFR2) (35), so we first confirmed that this 
receptor is expressed in TICs from T and SEZ (Supplementary Fig. S16). We next 
quantified the expression of VEGF and PDGF receptors. No significant difference was 
present between T and SEZ (no VEGFR1 nor VEGFR3 probe was available in the Illumina 
arrays) (Supplementary Table S6).
Exposure to Cisplatin and Cediranib revealed resistant TICs in T and SEZ together with a 
heterogeneous response profile (Fig. 4B and Supplementary Fig. S14B). Whereas sp17 and 
sp23 showed sensitivity to these treatments in T and SEZ, a significant response was 
observed only in one of the two regions for sp13, sp20 and sp52 (Fig. 4B).
The drug response profile of TICs from T and SEZ of the same patients emphasizes their 
potential utility in drug development compared to standard glioma cell lines e.g. U87 and 
human fetal neural stem cells (HFNSCs). U87 significantly responded to treatment with 
TMZ, Cisplatin and Cediranib whereas two HFNSCs lines (HFNSC and HFNSC1) were 
resistant to TMZ, as previously reported (37) and to Cisplatin and Cediranib (Supplementary 
Fig. S17).
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Phylogenetic reconstruction suggests different patterns of GB evolution involving SEZ 
malignant cells
Our genomic and chemo-response assays data show that the SEZ harbors malignant cells 
that contribute to tumor growth and murine models of GB indicate that the SEZ is enriched 
for tumor ancestors (2, 38-40). However, this has not been confirmed in GB patients. We 
analyzed SEZ and T samples to determine if tumor cells grow out of the SEZ or into the 
SEZ. We reconstructed tumor ancestral trees in 8 patients, using several genomic 
measurements derived from multiple spatially separated samples taken from the GB mass 
(T1-T6) and SEZ. We have previously employed this approach to describe intra-tumor 
heterogeneity in T and infer tumor evolution (7) and we now used FGMS to position the 
SEZ. In particular, we reconstructed phylogeny based on genome-wide DNA copy number 
(41). In an independent assay, we exploited the observation that cells record their ancestral 
history in the form of neutral DNA methylation patterns (42, 43). This analysis is not biased 
by the presence of non-neoplastic cells as only highly proliferative tissues accumulate 
sufficient methylation events (tumors and colonic epithelium) (44) (Fig. 5A). We first 
validated the molecular clock loci chosen for this analysis (Fig. 5, B and C, top) and then 
calculated the normal cell content in SEZ and T. The values of cellularity indicate no 
significant difference (Fig. 5, B and C, bottom).
These orthogonal techniques yielded highly concordant phylogenies: in sp52, sp54, sp56 and 
sp57, the SEZ harbors tumor precursor cells that gave rise to the GB mass (Fig. 5D). In sp42 
and sp49, we observed a similar trend although the two methods are not in full agreement 
(Fig. 5D). Analysis of sp55 and sp58 suggests a different pattern of evolution and 
emphasizes the heterogeneous nature of GB (Fig. 5D). Taken together, these data suggest 
that the SEZ contains a reservoir of malignant cells that are either tumor precursor clones or 
clones generated during GB evolution.
Discussion
Our comprehensive phenotypic, genomic and functional analysis reveals residual disease in 
the SEZ of GB patients (Fig. 1A and Supplementary Fig. S1, A and B). TICs are present in 
T and SEZ of the same GBs (Fig. 3C and Supplementary Fig. S10) and show differential 
patterns of therapeutic responsiveness and drug resistance (Fig. 4, A and B and 
Supplementary Fig. S14, A and B), suggesting that the SEZ should be considered as a novel 
potential therapeutic target in a subset of GB patients. This is confirmed by phylogenetic 
reconstruction showing different patterns of tumor evolution with the SEZ harboring 
precursor clones or clones generated during the GB growth (Fig. 5D).
Gene expression profiling of SEZ reveals that different GB subtypes (6) are present within 
the same patient. The SEZ is predominantly Mesenchymal (7 patients) or Classical (2 
patients). T is more diverse, with representation from all four subtypes (Fig. 2D). Thus it is 
possible to envisage a spectrum of expression patterns with Mesenchymal/Classical 
representing proliferative diversification at the tumor core.
Previous reports suggested that proximity to the SEZ predicts a multifocal tumor phenotype 
and recurrences that arise at locations distant from the initial lesion (45). More recently it 
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has also been reported that contact of the tumor mass with the SEZ correlates with shorter 
survival (46). To explore this, we isolated TICs from T and SEZ of the same patients. TICs 
have been described in human GB but no analysis based on FGMS has been performed. Our 
results show that in vivo both T- and SEZ-derived cells generated tumors, however cells 
from T are more tumorigenic in comparison to the SEZ in agreement with the CNAs of the 
patient samples showing a trend towards a smaller number of aberrations in the SEZ. These 
data suggest that the tumorigenic potential is exacerbated when increased genetic alterations 
are acquired by the cancer genome in line with previous reports (47, 48).
Since genomic and phenotypic analyses suggest that the SEZ harbors tumor cells, it is 
crucial to investigate whether there are differences in response to therapy in cells isolated 
from this region. It has been previously shown that patient-derived TICs accurately represent 
parent disease (27) and have potential application in high-throughput drug screening (28, 
29). Our data reveal that TICs from T and SEZ of the same GBs show different patterns of 
response to therapies that represent the current standard of care (Fig. 4, A and B, 
Supplementary Fig. S14, A and B and Supplementary Table S5). This suggests that they 
should be targeted using different approaches. Our results also reveal that a clinically 
significant fraction of cells is resistant to current treatments. This is consistent with murine 
data (3) indicating that multi-modal stratified approaches will be essential to improve 
therapeutic responsiveness.
GB evolves by following poorly understood spatial and temporal dynamics arising from 
cells of origin that are yet to be defined. The presence of malignant cells in the SEZ suggests 
two different scenarios of evolution with the GB growing into the SEZ or out of this region. 
Our phylogenetic data indicate that in 4/8 patients a pool of malignant precursor clones 
evolved in the SEZ (Fig. 5D). Given the presence of neural stem cells in the adult human 
SEZ (49), it has been suggested that GB is derived from those cells (50). This concept has 
been investigated in mouse models (2, 38-40), but until now there has been no direct 
evidence of the contribution of SEZ cells in human gliomagenesis. We show that the SEZ is 
a reservoir of disease and could be targeted therapeutically. Consistent with this, preliminary 
evidence suggest that irradiation of the SEZ in GB patients is associated with improved 
progression-free survival (51, 52).
In summary, we present a phenotypic, genomic and functional analysis of residual disease in 
human GB (Supplementary Fig. S18, A and B). Our approach together with FGMS provides 
a coherent strategy for interrogating the mechanistic basis of clinical heterogeneity in future 
studies. This is likely to further refine our understanding of the complex molecular 
landscape of GB, resulting in improved therapeutic strategies specifically aimed at targeting 
the SEZ.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Identification of SEZ in human GB
(A) Top panel. Illustrative MRI scans of a GB in the right temporal lobe. Red dots indicate 
tissue sampling from T and SEZ. Middle panel. Peri-operative images of visible 
fluorescence from T and SEZ indicating the presence of tumor tissue. Bottom panel. 
Haematoxylin&Eosin staining of T and SEZ. Both show cardinal features of GB (high 
mitotic index, nuclear atypia, mitosis and microvascular proliferation). Scale bar, 100 μm. 
(B) T and SEZ tissues have been stained for Gfap (green), Nestin (red), CD31 (pink) and 
counterstained with DAPI (blue). SEZ is characterized by Gfap expression and high 
vascularization. Scale bar, 100 μm. (C) Quantitative analysis of Gfap-, Nestin- and CD31-
positive cells in T and SEZ tissues of the same patient.
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Figure 2. The SEZ harbors residual disease
(A) Summary of the most common putative drivers in GB. In 6/8 patients the SEZ contains 
an equal or smaller number of aberrations with respect to its corresponding T. Cultured cells 
from T and SEZ of patient sp14 have been used for comparison with the corresponding 
tissues. (B) FISH of 3 patients confirms gain of the region of chromosome 7 including 
EGFR and the centromere (centr 7) in sp49 and sp58 (T and SEZ in both cases) and gain of 
the region including MET and centr 7 in sp58 and cells from sp14 (T and SEZ in both 
cases); as expected, based on copy number data, gain of MET was not observed in sp49T. 
Orange denotes EGFR or MET and green the centr 7. The single nuclei are representative of 
what was generally observed in each sample. (C) Clustering of gene expression profiles 
from 9 patients reveals that 5 SEZ samples cluster tightly together instead of with their 
matched T. Samples are color-coded based on their origin. (D) Each compartment of 9 GBs 
has been assigned to a previously described classifier (6): T samples are either Proneural, 
Classical, Mesenchymal or Neural and 7/9 SEZ are Mesenchymal.
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Figure 3. TICs can be isolated from SEZ of GB patients
(A) Cells from T and SEZ form spheres in serum-free medium. Magnification 100×; scale 
bar 50μm. (B) Left. Growth curve analysis shows that cells from T and SEZ are capable of 
long-term expansion. Right. Limiting-dilution assays reveal similar frequencies of sphere-
formation in T and SEZ. Each data point represents the average of triplicates. Error bars, s.d. 
(C) Top. Cumulative Kaplan-Meier survival analysis of 30 animals reveals the tumorigenic 
potential of T and SEZ cells from 5 GBs. There is a statistically significant difference (p-
value <0.05, Logrank test) between the survival of animals injected with T cells versus those 
injected with SEZ cells. Bottom. Table summarizing the number of tumors/injections and 
the type of cells used (primary or briefly cultured). (D) Haematoxylin&Eosin staining of T 
and SEZ cells-derived xenografts. Scale bar, 30 μm.
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Figure 4. TICs from SEZ contribute to drug resistance
Cells from T and SEZ of 4 patients were used to evaluate response to chemotherapeutics. 
(A) Differential response patterns to temozolomide (TMZ) were observed in T and SEZ 
cells of the same patients. Dose escalation has little impact on drug-resistant cells. (B) 
Distinct patterns of response are observed when the assay is performed with Cisplatin and 
Cediranib. Data are shown as normalized to control. The mean normalized absorbance as 
well as the minimum (−) and maximum (+) absorbance are plotted. Asterisks indicate 
statistical significance.
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Figure 5. Phylogenetic reconstruction reveals different patterns of tumor evolution involving 
SEZ malignant cells
(A) Cartoon illustrating the phylogeny based on molecular clock analysis. Non-dividing 
tissues, such as heart and brain, do not undergo mitotic events and do not accumulate 
methylation errors. Epithelial tissues, such as colon, show increased methylation with age 
due to the mitotic turnover of cells maintaining tissue homeostasis. Tumors undergo a large 
number of divisions and accumulate methylation changes in a manner proportional to the 
number of mitotic events. (B, C) Top. The IRX2 locus on chromosome 5 (in B) and the 
NETO1 locus on chromosome 18 (in C) have been validated as molecular clock loci by 
verifying that age-related methylation increases as a result of cell division in patient-derived 
tissues by comparing heart, brain and colon. Bottom. The graphs show tumor cellularity 
using IRX2 (in B) and NETO1 (in C) molecular clock data. The values of cellularity 
indicate no significant difference between T and SEZ. (D) Tumor phylogenies based on SEZ 
and multiple tumor mass samples (T, T1-T6) were reconstructed independently with 2 
methods: copy number breakpoints (a) and two molecular clock loci (b, IRX2 and c, 
NETO1). As an example, in sp52 the SEZ (blue) harbors cells that arise earlier than tumor 
mass cells (red) (sample T1 failed hybridization). NA= not available.
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